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ABSTRACT: Polymer-based amorphous solid dispersions
(ASDs) comprise one of the most promising formulation
strategies devised to improve the oral bioavailability of poorly
water-soluble drugs. Exploitation of such systems in marketed
products has been limited because of poor understanding of
physical stability. The internal disordered structure and
increased free energy provide a thermodynamic driving
force for phase separation and recrystallization, which can
compromise therapeutic eﬃcacy and limit product shelf life. A
primary concern in the development of stable ASDs is the
solubility of the drug in the polymeric carrier, but there is a
scarcity of reliable analytical techniques for its determination.
In this work, terahertz (THz) Raman spectroscopy was introduced as a novel empirical approach to determine the saturated
solubility of crystalline active pharmaceutical ingredient (API) in polymeric matrices directly during hot melt extrusion. The
solubility of a model compound, paracetamol, in two polymer systems, Aﬃnisol 15LV (HPMC) and Plasdone S630
(copovidone), was determined by monitoring the API structural phase transitions from crystalline to amorphous as an excess of
crystalline drug dissolved in the polymeric matrix. THz-Raman results enabled construction of solubility phase diagrams and
highlighted signiﬁcant diﬀerences in the solubilization capacity of the two polymer systems. The maximum stable API-load was
20 wt % for Aﬃnisol 15LV and 40 wt % for Plasdone S630. Diﬀerential scanning calorimetry and XRPD studies corroborated
these results. This approach has demonstrated a novel capability to provide real-time API−polymer phase equilibria data in a
manufacturing relevant environment and promising potential to predict solid-state solubility and physical stability of ASDs.
KEYWORDS: amorphous solid dispersion, API−polymer solubility, Terahertz-Raman spectroscopy, stability prediction
■ INTRODUCTION
Poor aqueous solubility is a major concern in the
pharmaceutical ﬁeld that can compromise the amount of
drug available for absorption, lead to low bioavailability, and
detract from the drug’s inherent therapeutic eﬃcacy.1,2 It is
expected that around 90% of the new chemical entities possess
poor aqueous solubility and fall into class II or IV of the
Biopharmaceutics Classiﬁcation System (BCS), limiting their
further development.3 Amorphous solid dispersions (ASDs)
comprise one of the most promising formulation approaches
developed to address this challenge. ASDs, where active
pharmaceutical ingredients (APIs) are molecularly dispersed in
amorphous polymeric carriers have been shown to achieve
faster dissolution rates and higher apparent solubility.4−7 Such
systems provide solubility enhancement primarily via API
amorphization; however, increased porosity and improved
wettability have also been reported as enabling factors.8 In the
amorphous state, the API is in its highest energy state and as a
result, no energy is required to break the crystal lattice and
amorphous materials generally have better aqueous solubility
than their crystalline counterparts.9,10 However, the internal
disordered structure and increased free energy provide a
thermodynamic driving force for phase separation and
recrystallization, which makes the design of stable ASDs highly
challenging.
Despite decades of pharmaceutical research since the ﬁrst
solid dispersion was developed in 1961 by Sekiguchi and
Obi,11 ASDs are still not fully exploited in marketed products.
Because of poor physical stability and lack of proper
understanding of the thermodynamic, kinetic, and molecular
aspects involved in the stabilization of these systems, their
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development is still largely by trial and error, being both time-
and resource-consuming.12,13 The solubility of the API in the
carrier polymer is one of the key factors determining physical
stability and API recrystallization propensity.14−16 Its determi-
nation is of paramount importance in the manufacture of
crystal-free, stable ASDs and is therefore of considerable
commercial importance with regard to shelf life of this class of
pharmaceutical products. If the API concentration in the
formulation is below the equilibrium solubility, the ASD will be
thermodynamically stable and will not recrystallize in the
absence of additional stress factors. When the API content
exceeds its thermodynamic solubility, the ASD becomes
supersaturated and API phase separation and recrystallization
are likely to occur.17 However, if the system is kinetically
stabilized at storage conditions, molecular mobility may be
slowed enough to retain the amorphous conﬁguration and
inhibit recrystallization during pharmaceutically relevant time
periods.18
Solubility determination of a drug in a polymer matrix is an
analytically challenging task as both components are normally
solid at room temperature and because of high viscosity of the
polymeric carrier, equilibrium solubility is diﬃcult to reach and
test.19,20 In fact, the current pack of “industry standard”
analytical techniques is limited in that it is often based on
diﬀerential scanning calorimetry (DSC) analysis or inferred
based on postproduction analysis, providing an account of the
material state after manufacturing is complete. The DSC
methods include the melting point depression method, the
recrystallization method, and the enthalpy approach amongst
others.14,19,21,22 Aside from thermal degradation and chemical
instability, these methods generally risk solubility under-
estimation because of low molecular mobility in a viscous
polymer (i.e., no mixing is applied) and require equilibrium
assumptions which limits their wider applications.
Because access to experimental solubility data is only
possible at high temperature, a number of thermodynamic-
based models have been adjusted to predict solubility at
storage conditions. A commonly employed model for this
purpose is based on the Flory−Huggins (FH) lattice theory.
Although it was never intended for systems in which hydrogen
bonding interactions are important, as is the case for most
ASDs, it has been eﬀectively applied to several polymeric
systems.23,24 Nonetheless, examples of inaccurate predictions
using this approach have also been reported.20,25 Alternative
methods include the empirical model by Kyeremateng et al.,26
and more recently, the Perturbed-Chain Statistical Associating
Fluid Theory (PC-SAFT) developed by Gross and Sado-
wski.27−29
There is a growing body of evidence suggesting that the
apparent solubility of an API in the polymer system may vary
according to the processing method used.30−32 This may be
driven by diﬀerences in mixing rather than true thermody-
namic equilibrium being reached. Within this work, a
corotating twin screw extruder was used as the mixing device.
This type of unit provides intense mixing and has the potential
to overcome kinetic limitations and reach true equilibrium.
Therefore, the objective of this study was to determine API
solubility directly during hot melt extrusion (HME) process-
ing. This was achieved by monitoring the API crystalline to
amorphous structural phase transitions taking place in the low-
frequency terahertz-Raman region as it dissolves in the
polymer. For this purpose, paracetamol (whilst not presenting
in vivo solubility constraints) was selected as the model
compound and two commercially relevant polymer systems,
Aﬃnisol 15LV (hydroxypropyl methylcellulose) and Plasdone
S630 (copovidone) as polymeric carriers, to assess the above
application of THz-Raman. Extrusion was performed at
diﬀerent API−polymer ratios and for each composition,
diﬀerent processing temperatures were explored to allow
phase-equilibria inferences and construction of temperature−
composition phase diagrams.
■ MATERIALS AND METHODS
Materials. Pharmaceutical grade granular paracetamol
(PCM) was purchased from Mallinckrodt Inc. (Raleigh,
USA). Hydroxypropyl methylcellulose grade Aﬃnisol 15LV
(AFF) and copovidone (PVP/VA 6:4) grade Plasdone S630
(PLSD) were kindly donated by Dow Inc. (The Dow
Chemical Company, Michigan, USA) and Ashland Inc.
(Columbus, OH, USA), respectively. The chemical structure
of all materials is displayed in Figure 1. All compounds were
used as obtained, without further puriﬁcation.
Methods. Preparation of ASDs by HME. HME was
performed with a Eurolab 16 Twin-screw extruder (Thermo
Scientiﬁc, Karlsruhe, Germany) equipped with two DDW-M
FW20 feeders (Brabender Technologie, Duisburg, Germany)
operating in the gravimetric mode with a vertical crammer
hopper (Brabender Technologie, Duisburg, Germany) set to
100 rpm. The experimental set-up was as illustrated in Figure
2. API and polymers were separately fed at diﬀerent feeding
rates to reach the desired API−polymer ratio. A combined
feeding rate of 1 kg/h was used. For all experiments, barrel
zone 1 was operated at 20 °C and barrel zones 2 and 3 were
controlled at temperature set points of 50 and 100 °C,
respectively, to prevent powder melting and blockage of the
feeding zone. The processing temperature limits of the
remaining barrel zones were constrained by the polymer
glass transition temperature (Aﬃnisol 15LV115 °C and
Plasdone S630109 °C) and the drug melting point (170
°C). This was required to assure the soften/liqueﬁed state of
the polymer (i.e., act as a “liquid solvent”) to mix and dissolve
the API, while keeping the API below its melting point to
enable detection of the excess crystalline API. Barrel sections
4−10 and die zone were controlled to the same temperature
set point values, which are reported in Tables 1 and 2. Product
melt temperature was monitored with a pressure−temperature
probe (Terwin Instruments Ltd., Bottesford, UK) immersed in
the polymer−API mixture within the conﬁnes of the die
section. The temperature values measured in barrel sections
4−10, the die and the product melt probe varied from reported
set point values less than ±3 °C. Therefore, within the present
work, we quote temperature values as the set-point temper-
ature values. Collected extrudates were pelletized and stored at
25 °C/60% RH until further analysis.
Figure 1. Chemical structure of (A) Paracetamol, (B) Aﬃnisol 15LV
and (C) Plasdone S630. “n” and “m” represent the structural unit for
both polymers. Plasdone S630 is a linear copolymer where n/m = 6/4
mass ratio.
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Terahertz-Raman API−Polymer Solubility Measurements.
A terahertz-Raman probe (Ondax Inc., USA) coupled with a
RNX1 Raman spectrometer unit (Kaiser Optical Systems Inc.,
USA) was immersed in the polymer API-mixture in an
adjacent port immediately beside the pressure temperature
probe to monitor the API structural phase transitions occurring
during extrusion. Data were collected with a 785 nm laser
excitation source operating at 70 mW power. An exposure time
of 2 s and three spectral accumulations were used. Spectra
were acquired with Holograms software (version 4.1) over the
−20 to 1800 cm−1 spectral range and integrated into
PharmaMV RealTime software (version 5.2, Perceptive
Engineering Ltd., Daresbury, UK) for real-time visualization.
Spectral preprocessing was performed with PharmaMV
Development software (version 5.2) applying Whittaker
smoothing and standard normal variate for baseline eﬀect
removal and normalization, respectively. Thermally induced
transitions in the low-frequency terahertz-Raman region (5−
200 cm−1/0.15−6.0 THz) were used to distinguish between
the crystalline and amorphous states of the API. Transition
temperatures from crystalline-to-amorphous and amorphous-
to-crystalline were used to determine the temperature−
composition coordinates at each API−polymer ratio and
construct the solubility phase diagram for both systems.
Oﬀ-Line Terahertz-Raman Spectroscopy. Oﬀ-line variable-
temperature THz-Raman analysis was performed to obtain the
reference spectra of each PCM polymorph and amorphous
paracetamol. Data were collected with the terahertz-Raman
probe (coupled with a RNX1 spectrometer unit) attached to a
Linkam LTS420 hot stage. To prepare the amorphous
paracetamol and the three polymorphs, the temperature
cycling method outlined by Nanubolu and Burley was
adopted.33 PCM samples of 3−5 mg were conﬁned between
a microscope glass and a cover slip and heated to 180 °C at a
rate of 20 °C/min and held at that temperature for 2 min.
Subsequent melt quenching to 0 °C was performed at a
cooling rate of 20 °C/min to obtain the amorphous glass form.
To obtain the paracetamol polymorphs, the amorphous glass
from these steps was then allowed to equilibrate at 0 °C for 5
min prior to a second heating cycle to 180 °C using a heating
rate of 1 °C/min. As the temperature rises at this slow heating
rate, the glass transforms to PCM form III, then form II, and
then form I before melting at ∼170 °C. Therefore the
reference spectra for the amorphous and three polymorphs
were gathered through this cycle. At the speciﬁc transition
temperatures identiﬁed (80 °C for form III, 120 °C for form II
and 150 °C for form I), the heating rate was paused and the
spectra was acquired using an exposure time of 2 s and three
spectral accumulations.
Figure 2. Schematic representation of the experimental HME set-up and screw conﬁguration.
Table 1. Hot Melt Extrusion Experimental Conditions for
PCM−AFF System
API
feeding
rate
(kg/h)
polymer
feeding rate
(kg/h)
processing temperature (°C)
(Barrel sections 4−10 and die zone)a
screw
speed
(rpm)
0.1 0.9 115, 130, 150, 170 200
0.2 0.8 115, 120, 125, 130, 140, 150 200
0.25 0.75 115, 120, 125, 130, 140, 150, 160, 170 200
0.275 0.725 115, 120, 125, 130, 140, 150 200
0.3 0.7 115, 120, 125, 130, 140 200
0.325 0.675 115, 120, 125, 130, 135, 140 200
0.35 0.65 115, 120, 125, 130, 135, 140, 145, 150 200
aEach value in this column represents a distinct experimental
condition and denotes the cumulative set-point barrel temperature
of sections 4−10 and die (i.e. zones 4−10 and the die were operated
isothermally).
Table 2. Hot Melt Extrusion Experimental Conditions for
PCM−PLSD System
API
feeding
rate
(kg/h)
polymer
feeding rate
(kg/h)
processing temperature (°C)
(Barrel sections 4−10 and die zone)a
screw
speed
(rpm)
0.3 0.7 110, 120, 130, 150 200
0.35 0.65 110 200
0.375 0.625 110, 120 200
0.4 0.6 110, 120, 130 200
0.425 0.575 110, 120, 130, 140 200
0.45 0.55 110, 120, 130, 140, 150 200
0.475 0.525 110, 120, 130, 140, 150 200
0.50 0.5 110, 120, 140, 150 200
0.525 0.475 150 200
0.55 0.45 150 200
0.575 0.425 150 200
0.6 0.4 150, 160 200
0.625 0.375 150, 160 200
0.65 0.35 150, 160, 170 200
0.675 0.325 150, 160, 170 200
0.70 0.3 150, 160, 170 200
aEach value in this column represents a distinct experimental
condition and denotes the cumulative set-point barrel temperature
of sections 4−10 and die (i.e. zones 4−10 and the die were operated
isothermally).
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Hot Stage Microscopy. Hot-stage microscopy (HSM)
experiments were conducted using a Leica DM2700 trans-
mission optical microscope (Leica Microsystems, Milton
Keynes, UK) under a cross-polarized light. The apparatus
was equipped with a Leica DF320 digital camera (Leica
Microsystems, Milton Keynes, UK) and a Linkam LTS420
T95 temperature control stage. Samples of 3−5 mg were
placed into the hot-stage chamber and heated to 180 °C at a
heating rate of 1 °C/min. Pure polymers and API−polymer
physical mixtures were subjected to isothermal steps of 3 min
at every 10 °C above 100 °C to equilibrate. The cooling cycle
to 0 °C was performed at a rate of 1 °C/min. Birefringence
properties of crystalline materials were used to distinguish the
crystalline API from amorphous API−polymer mixtures. Pure
PCM samples were conﬁned between a microscope glass and a
cover slip and subjected to an additional heat cycle to assess
recrystallization behavior from the amorphous glass.
Diﬀerential Scanning Calorimetry. All experiments were
performed on a DSC 214 Polyma diﬀerential scanning
calorimeter (Netzsch-Geraẗebau GmbH, Germany) under a
helium environment (purge 1 = 40 mL/min, purge 2 = 60 mL/
min). Samples of 3−5 mg were accurately weighed and
crimped in 25 μL aluminium pans with pierced lids and
subjected to heat-cool-heat cycles. Heating cycles were
performed to 180 °C at a heating rate of 20 °C/min. Cooling
was performed from 180 to 0 °C at 20 °C/min.
X-ray Powder Diﬀraction. Variable temperature powder
diﬀraction data (VT-XRPD) were collected using a Bruker D8
ADVANCE II diﬀractometer (Bruker Ltd., Coventry, UK)
equipped with θ/θ geometry and primary monochromated
radiation (Cu, λ = 1.54056 Å). Data were collected in the 2θ
range of 4°−35° using a step size of 0.017° and 1 s/step speed.
Operating voltage and current were 40 kV and 50 mA,
respectively. Pure PCM samples were placed into 0.7 mm
borosilicate glass capillaries and subjected to heat-cool-heat
cycles to 180, 0 and 180 °C, respectively. Heating and cooling
rates of 6 °C/min were employed because of instrumental
limitations. Identiﬁcation of the crystalline form was made by
comparison to CCSD crystalline forms I, II, and III
(HXACAN27, HXACAN31 and HXACAN29, respectively)
using Mercury software (version 3.9).
HME extrudates were analyzed at ambient temperature and
data were collected on a Bruker AXS D8 ADVANCE
transmission diﬀractometer equipped with the θ/θ geometry,
primary monochromated radiation (Cu Kα1 λ = 1.54056 Å),
and an automated multiposition x−y sample stage. Samples
were mounted on a polyimide ﬁlm (Kapton, 7.5 μm thickness)
and analysis was performed in the angular range of 4°−35° 2θ
with a 0.017° 2θ step size and 2 s per step count time.
■ RESULTS AND DISCUSSION
Saturated Solution Temperature (TS) Determination.
The main premise required to construct an API−polymer
solubility phase diagram is the determination of the temper-
ature at which a given crystalline API content is soluble in the
polymer matrix. Access to this temperature was directly
obtained during HME by monitoring the API structural
phase transitions from crystalline to amorphous as it dissolved
in the polymeric carrier. These phase transitions were
monitored in the low-frequency THz-Raman spectral region
that covers the Stokes signal (5−200 cm−1) and provides
information about the crystal lattice vibration (phonon)
modes.34,35 Such vibrations are sensitive to local order and
disorder, enabling distinction between diﬀerent crystal packing
arrangements, including the amorphous and crystalline
states.36,37
THz-Raman spectra of PLSD, AFF, amorphous, and
crystalline PCM are shown in Figure 3. Crystalline PCM has
distinctive peaks at 32, 56, and 89 cm−1 which are
characteristic to form I.33 Given the lack of the long-range
structural order in amorphous materials, these lattice modes
are absent in the amorphous drug form and in both polymeric
matrices and were used to diﬀerentiate between amorphous
and crystalline PCM within the API−polymer mixtures. As the
API dissolves in the polymer, the crystalline structure is
disrupted and the drug is rendered amorphous. Therefore, to
assure the robustness of the method, API solubility was
determined by cycling extrusion temperature up, to induce
dissolution and down, and to force drug precipitation.
As an example, Figure 4 illustrates the normalized spectra
used to determine the saturated solution temperature (TS) for
PCM−AFF 30−70 wt % (A−B) and PCM−PLSD 45−55 wt
% (C−D). As TEXTRUSION approaches TS, the drug
progressively dissolves in the polymer and the intensity of
the lattice modes associated with crystalline PCM decreases
until disappearing at 130 °C for PCM−AFF 30−70 wt %
(Figure 4B) and 150 °C for PCM−PLSD 45−55 wt % (Figure
4D), when the API content is fully amorphous. TS was then
estimated at the intermediate point between the API
amorphous and crystalline phases, corresponding to 127.5 °C
for PCM−AFF 30−70 wt % and 145 °C for PCM−PLSD 45−
55 wt %. It should be noted that to demonstrate the technique,
TS was approached by varying extrusion temperature using
relatively large steps of 5 °C p/step for PCM−AFF and 10 °C
p/step for PCM−PLSD. Therefore, solubility estimation is
associated with an error of at least ±2.5 °C for PCM−AFF and
±5 °C for PCM−PLSD.
Additionally, the product melt temperature may diﬀer from
set point temperature values as a result of heat from the shear
between the screws and material, so care should be taken with
regard to barrel zone temperature measurements and actual
local material temperatures.38,39 Within this work, product
melt temperature was monitored at the die section and typical
± variation did not exceed 3 °C compared to the system set
Figure 3. Normalized THz-Raman spectra of PLSD (green), AFF
(blue), amorphous PCM (red) and crystalline PCM (black).
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Figure 4. THz-Raman spectral evolution of (A,B) PCM−AFF 30−70 wt % and (C,D) PCM−PLSD 45−55 wt % at diﬀerent processing
temperatures. In Figure (B,D) spectra are spatial averages of 20 spectra at each temperature.
Figure 5. Phase behavior of PCM−AFF system during extrusion: (A) HME processing temperatures and API physical state; (B) estimated
equilibrium solubility curve. Cc denotes the critical concentration up to which no crystallinity was found.
Figure 6. Phase behavior of PCM−PLSD system during extrusion: (A) HME processing temperatures and API physical state; (B) estimated
equilibrium solubility curve. Cc denotes the critical concentration up to which no crystallinity was found; * denotes compositions expected to be
crystalline at 140 °C based on crystallinity of adjacent compositions; ** denotes the composition range where the API amorphous character is not a
direct reﬂection of the polymer solubilisation capacity due to the proximity to the API Tm.
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point value. In the upstream sections, the extent of heating and
cooling required to maintain set-point temperatures was
examined. This showed that there was no substantial cooling
requirement to compensate for frictional heat. Therefore, it
was assumed that the reported temperature values are reﬂective
of the local materials temperature within the system.
Using the same approach, TS was determined for all API−
polymer compositions. For both systems, temperature−
composition phase diagrams were generated by plotting the
lowest temperature required for complete API amorphization
(API dissolution end temperature) and the highest temper-
ature at which residual crystalline API could be detected.
Figures 5 and 6 show the amorphous and crystalline
coordinates and the estimated equilibrium solubility curve as
a function of the HME processing temperature for both
systems.
Temperature−Composition Phase Diagrams. The
drug phase-transition region demarks the boundary between
the undersaturated region (region I in Figures 5B and 6B)
where the API is fully amorphous and the supersaturated
region (region II in Figures 5B and 6B), where crystalline API
particulates are suspended in a supersaturated API−polymer
matrix. At certain API−polymer ratios, API dissolution showed
no temperature dependence and complete miscibility was
observed at all processing temperatures, including the polymer
glass transition temperature (Tg). This was considered as the
critical concentration (Cc) as it deﬁned the maximum API
concentration where no crystallinity was found. The
experimental limiting factor determining the lowest HME
processing temperature for each system was the polymer Tg, to
avoid solidiﬁcation of the polymer and hence equipment
blockage. Figure S1 shows the THz-Raman spectra at the
critical concentration for both systems.
Paracetamol−Aﬃnisol 15LV System. For Aﬃnisol-based
compositions, the API critical concentration was 20 wt %
(Figure 5). Upon further increase of the API mass fraction,
equilibrium solubility is reached at higher temperatures and an
almost linear temperature increment is observed for mixtures
≥27.5 wt % API-load. This observed trend is most likely to be
a result of the relatively large temperature steps taken at the
given compositions (5 °C per step). Reducing the temperature
steps could improve the accuracy in determining the position
of the equilibrium temperature and reﬁne the shape of the
curve.
For all experimental compositions, the API dissolved at
temperatures well below its melting point (e.g., 55 °C lower at
20 wt % API-load). This is indicative of good miscibility
between the components and suggests a marked reduction of
the drug’s chemical potential in the presence of the polymer.40
The reduction in the chemical potential is usually observed
using DSC through detection of a depressed melting
point.22,41However, these results show that spectroscopic
methods can also be used to indirectly assess these
phenomena. Moreover, this is a direct observation that
extrusion can be performed at temperatures below the API
melting point and attain complete drug solubilization. The
correlation between the HME processing temperature, drug
composition, and residual crystallinity has been pointed out to
be of utmost importance to deﬁne HME processing boundaries
and identify the optimal processing window to promote
formation of molecular dispersions whilst avoiding drug/
polymer degradation.42,43 This is particularly relevant for ASDs
containing thermally labile drug substances.
Paracetamol−Plasdone S630 System. Compared to
Aﬃnisol, Plasdone exhibited higher solubilization capacity
and the API critical concentration up to which there was no
detected free API was 40 wt % (Figure 6). When increasing the
API content from 45 to 60 wt %, TS appears to reach a plateau,
remaining at 145 °C despite the drug increase. Note that
physical mixtures from 52.5 to 57.5 wt % API (identiﬁed by
single asterisk in Figure 6A) were only extruded at the
dissolution end temperature (150 °C). However, given the
crystalline character of adjacent concentrations at 50 and 60 wt
% API at 140 °C, it is reasonable to assume crystallinity of this
intermediate concentration range at 140 °C.
Apart from the impact of the temperature steps taken at each
composition (10 °C/step) the “plateau eﬀect” is thought to be
related to temperature-dependent structural changes of the
polymer. It has been described that PVP-based polymers could
assume helical conformation under speciﬁc circumstances
which potentially could also occur during extrusion.44 This
conformation would enable incorporation of additional drug
molecules upon expansion, by reducing steric hindrance of API
molecules already linked to the polymeric chain, and could
explain the solubility increase despite the constant temper-
ature. Further investigation is required to provide experimental
support for this hypothesis, but this was out of the scope of the
present work.
From 60 to 62.5 wt % API, TS experiences an abrupt
temperature increment. Above 65 wt % API-load, as
TEXTRUSION approaches the API melting point, the amorphous
state of the drug is not a reﬂection of the polymer
solubilization capacity. This is one of the limitations of this
approach because it requires (i) miscible API−polymer
systems where the API Tm > polymer Tg and (ii) processing
temperatures below API Tm to enable detection of the excess
crystalline API.
When comparing to PC-SAFT and FH predictions
performed by Lehmkemper and co-workers,29 there are
evident diﬀerences between predictions and experimental
measurements performed in this study. PC-SAFT and FH
predictions lack the plateau eﬀect and solubility equilibrium is
usually lower than the one determined by THz-Raman,
especially at high polymer content. Even though the shape of
the solubility curve and speciﬁc saturation temperatures diﬀer,
the magnitude of the values is of the same order. The work of
Lehmkemper and co-workers shows that the maximum stable
concentration of API in this polymer lies between 30 and 40%,
which is comparable to the critical concentration determined
during this work using extrusion-THz (i.e., 40 wt %). This
suggests that this critical concentration could indicate the solid
solution capacity of the polymer after HME processing and
thus provides a concentration threshold that can diﬀerentiate
stable/amorphous systems from metastable/unstable systems.
This correlation will be elaborated upon in more detail later
on.
Polymorphic Phase Identiﬁcation. In order to assess
eventual polymorphism occurring during extrusion, variable-
temperature oﬀ-line THz-Raman experiments were performed
to obtain THz reference spectra of each polymorph. We used
constrained crystallization under a microscope slide and a
cover glass to kinetically trap polymorphs via the Ostwald rule
of stages. Paracetamol has three known polymorphs under
normal pressure conditions: monoclinic (form I, stable),
orthorhombic (metastable, form II), and form III, the most
metastable of all.45,46 Its recrystallization behavior from the
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amorphous glass is highly variable and dependent on both
sample thermal history and the presentation method.47
Therefore, HSM, DSC, and variable-temperature XRPD
experiments were performed as conﬁrmatory techniques
(results shown in Figures S2 and S3 in the Supporting
Information section).
Collected THz-Raman spectra of polymorphs III, II, and I,
as well as the amorphous form are shown in Figure 7. By
comparing the THz-Raman spectra obtained during HME with
the reference spectra of each polymorph, only PCM form I was
identiﬁed for both systems. There were no metastable
crystalline forms during the API solubilization process nor
recrystallization from the amorphous form during extrusion.
Hence, measured solubility depicts PCM form I solubility in
both matrices. However, recrystallization to diﬀerent poly-
morphs could occur after HME for supersaturated systems.
Crystal Dissolution Behavior Observed by Hot-Stage
Microscopy. It is interesting to note that at Tg of pure
polymer, thermal diﬀusion and molecular mobilityessential
to the mixing of the two chemical entitieswere suﬃcient to
fully dissolve the API up to Cc in both polymeric matrices
during the short residence time in the extruder (∼150 s for
empty extruder conditions). Traditional DSC solubility
protocols disregard solubility data near Tg because drug
dissolution kinetics becomes much slower than the time scale
of the measurement.12 However, the energy provided during
extrusion via intensive mixing, shear stress, and temperature
input was suﬃcient to overcome this barrier and dissolve the
API. Thus, as an alternative means of understanding the
thermodynamic driving force for crystal dissolution, HSM
experiments were carried out to simulate the temperature
conditions of the HME process by using isothermal steps of
equal duration as the mean residence time within the extruder
(empty barrel conditions).
Figure 8 shows the representative micrographs at the end of
the isothermal steps in both polymeric matrices and sample
Figure 7. THZ-Raman spectra of amorphous PCM and crystalline
forms III, II and I with respective recrystallisation temperatures from
the amorphous glass.
Figure 8. Hot stage microscopy images of (A) pure AFF; (B,C) PCM−AFF 20−80 wt % during heating and cooling cycles, respectively; (D) pure
PLSD upon heating cycle; (E,F) PCM−PLSD 30−70 wt % during heating and cooling cycles, respectively. The scale bas is as indicated for all
images.
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behavior during cooling cycles. Based on the birefringence
properties, there is no observable API dissolution at the
polymer Tg, as both systems comprise just physical mixtures.
Apart from heat transfer variations, without the HME-induced
distributive and dispersive mixing, API dissolution is diﬀusion
controlled (i.e., there is no mixing) and complete API
dissolution occurs at higher temperatures, possibly due to
kinetic constraints. However, upon complete dissolution, a
single phase system is obtained, corroborating THz-Raman
indication of miscibility. For both polymer systems during
HSM analysis, there is no API recrystallization upon cooling,
indicating that both polymers are capable of stabilizing the
amorphous drug. The absence of recrystallization is also
partially related to the intrinsic glass forming ability of the
drug.48 There is also evidence of a marked API-induced
plasticization eﬀect. When in a single component system,
Plasdone S630 (Figure 8D) experiences a drastic change in the
viscoelastic properties with apparent liquefaction occurring at
160 °C (∼50 °C above its Tg), whereas pure Aﬃnisol (Figure
8A) has higher viscosity and no evident liquefaction is
observed up to 180 °C.
Predictive Value of the Critical Concentration. To
validate our hypothesis with respect to the use of the critical
concentration as a stability predictor, DSC and X-ray
diﬀraction analysis were performed to assess the physical
state of the extrudates after extrusion. For this purpose, only
samples processed at the dissolution end temperature (lowest
temperature required for complete API amorphisation) were
considered for each composition.
DSC thermograms of PCM, AFF, and PCM−AFF
extrudates are displayed in Figure 9A. Up to the critical
concentration (Cc = 20 wt %), there is no evidence of
endothermic events because of melting of the crystalline
material. For drug loadings >20 wt %, there is an exotherm at
140−150 °C depicting partial recrystallization to form II, and
two melting endotherms at ∼155 and 170 °C, ascribed to
melting of forms II and I, respectively.
XRPD analysis (Figure 9B) conﬁrmed the lack of
crystallinity up to 20 wt % drug loading, as indicated by the
halo pattern characteristic of amorphous materials. In contrast,
Bragg peaks corresponding to PCM form I were found for all
concentrations above Cc. An additional diﬀraction peak with
maxima at ∼32° (2θ) was observed in the diﬀractograms of
pure Aﬃnisol and all low API-loading extrudates. This peak is
ascribed to NaCl that is used as a manufacturing additive for
Aﬃnisol 15LV up to 5 wt %. It should be noted that NaCl was
not spectrally active in the THz-Raman region and therefore
had no contribution to crystallinity detected during extrusion.
The same recrystallization trend is observed for Plasdone-
based extrudates. Up to the critical concentration (Cc = 40 wt
%), there is a single-phase amorphous dispersion with no
melting endotherms (Figure 10A). At 42.5, 45 and 50 wt %,
the small melting endotherm at 169 °C, denotes melting of
PCM form I. At higher drug loadings, there are two
endotherms at ca. 160 °C (melting of form II) and 169 °C
(melting of form I). X-ray diﬀraction analysis is depicted in
Figure 10B. It corroborated the amorphous character of the
extrudates up to the Cc. For formulations ≥42.5 wt %,
crystalline peaks corresponding to form I were found and as
expected, their intensity increased with increasing the API
mass fraction. Given its absence in the XRPD patterns, form II
is thought to be thermally induced by the DSC heating scan for
both polymers.
Appearance of crystalline API following cooling of the
extrudates suggests that the solubility limit has been exceeded.
This was evident for all API−polymer extrudates with drug-
loadings above Cc (i.e., >20 wt % for PCM−AFF and >40 wt
% for PCM−PLSD). This oﬀers compelling evidence that (i)
THz-Raman identiﬁcation of the saturated solution temper-
ature is valid and (ii) that the critical concentration has the
ability to diﬀerentiate ASD formulations that are truly
unstable/metastable and those which are more likely to be
stable at the point of use. Based on the correlation between Cc
and DSC and XRPD amorphicity, the maximum solubility of
paracetamol at temperatures encountered post HME in
Aﬃnisol and Plasdone are ≤20 and ≤40 wt % respectively.
Thus, Cc appears to provide a maximum drug-loading
threshold that can be used to infer ASD physical stability at
the point of developing the manufacturing process. This
enables early identiﬁcation of recrystallization tendencies
within an ASD and allows identiﬁcation of the maximum
API load that can be molecularly dispersed in the polymer
during extrusion and remain amorphous at the point of use.
The THz-Raman method herein developed has allowed us
to obtain an insight into the likely equilibrium solubility range
for these particular systems. Care was taken to allow extrusion
to reach the steady state at each experimental condition and
THz-Raman data were only considered when steady state
conditions were satisﬁed. This allied with the length of the 16
mm extrusion unit (HME length (L)/diameter (D) = 40) and
the intensive mixing provided oﬀers suﬃcient conﬁdence to
assume true equilibrium was reached and that observed
solubility data are not constrained by kinetic limitations.
Figure 9. (A) DSC thermographs and (B) XRPD diﬀractograms of
PCM, AFF and PCM−AFF extrudates with diﬀerent API contents.
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Furthermore, by enabling in-line drug-polymer solubility
determination, this method also provides a valuable process
analytical technology (PAT) tool for process optimization
during the development of new ASDs systems by HME. It has
also the potential to correlate product critical quality attributes,
such as residual crystallinity, to HME critical process
parameters such as residence time, screw speed, feed rate,
screw conﬁguration, and processing temperature, as promoted
by the International Conference on Harmonization (ICH) Q8
(R2) and quality by design (QbD) approaches advised by
regulatory authorities, namely Food and Drug Administration
(FDA) and European Medicines Agency (EMA). Apart from
the processing temperature, these parameters were not allowed
to vary in this ﬁrst exploratory study but will be considered in
future experiments.
■ CONCLUSIONS
The objective of this study was to explore a new method to
enable solubility determination of crystalline API in polymeric
matrices directly during HME. For the ﬁrst time, low-
frequency terahertz-Raman spectroscopy was coupled with
HME to monitor the drug structural phase transitions as a
means of providing real-time solubility. As a proof of concept,
the solubility of Paracetamol in Aﬃnisol 15LV and Plasdone
S630 was determined. Successful identiﬁcation of the saturated
solution temperature enabled construction of solubility phase
diagrams for the binary systems. From the phase diagrams
generated in this manner, a critical API concentration was
identiﬁed, 20 wt % for Aﬃnisol 15LV and 40 wt % for
Plasdone S630. This critical concentration was found to reveal
the maximum API load that can be molecularly dispersed in
the polymer during extrusion and remain in the amorphous
state at storage conditions after HME. DSC and XRPD
analysis supported this inference and showed that this critical
concentration could be used as a stability predictor.
Overall, solubility data generated by this approach provide a
more accurate reﬂection of the likely solubility equilibrium for
optimum HME processing at temperatures below the API Tm
and a reliable alternative solubility measurement for determin-
ing stable ASDs. This approach also oﬀers an important in-line
process control tool for process optimization and QbD
implementation in the manufacture of HME-based ASDs.
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